GC CELL's CIK Cell Therapy Study for Glioblastoma Published in International Journal

[Financial News] GC CELL published a study on the treatment of glioblastoma using cytokine-induced killer (CIK) cells in an international journal.
GC CELL said on the 1st that a study analyzing the potential application of CIK cells to glioblastoma had been published in the international journal Frontiers in Neurology.
The study was a researcher-initiated retrospective real-world data analysis that examined the clinical applicability of CIK cell therapy by integrating analyses of patient-derived CIK cells, preclinical studies, and actual patient treatment data.
The clinical analysis retrospectively reviewed the medical records of 12 patients with recurrent glioblastoma who received autologous CIK cell therapy. The patients also received Temozolomide, Bevacizumab, Nivolumab, and other treatments in combination with CIK cell therapy.
The analysis found that the median progression-free survival (PFS) for the entire patient group was 10.5 months, while the median overall survival (OS) was 14.2 months. No patients discontinued treatment because of CIK cell therapy, and no cases of cytokine release syndrome (CRS), severe allergic reactions, or treatment-related deaths were observed.
However, the study had several limitations: the sample size was small, with only 12 patients; the combination treatments varied by patient; and it was a retrospective exploratory study without a control group. Therefore, the observed survival periods cannot be interpreted as the direct effects of CIK cell therapy.
Glioblastoma is a representative malignant brain tumor in adults. It frequently recurs even after standard treatment, and treatment options are limited following recurrence. Based on this study, GC CELL plans to continue research evaluating the potential of CIK-based cell therapy for refractory solid tumors, including glioblastoma.
Choi Jong-kwon, a professor of hematology and oncology at Konyang University Hospital and the corresponding author of the study, said, "Glioblastoma is a type of cancer for which treatment options are limited after recurrence, and immunotherapy is also difficult to apply. This study is significant because it explored the clinical applicability and safety of CIK cell therapy for recurrent glioblastoma by analyzing the characteristics of CIK cells and the results of animal-model studies together with real-world clinical data."
Won Seong-yong, CEO of GC CELL, said, "This study is significant because it expanded GC CELL's CIK cell therapy research capabilities, accumulated through Immuncell-LC Inj., into refractory solid tumors such as glioblastoma. We will continue to build evidence to validate the potential of cell therapy for cancers with high unmet medical needs and expand our collaboration with researchers in Korea and abroad."

[email protected] Jung Sang-hee Reporter